Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 4/20 | 0.36 |
| ▸ | MAOB | P27338 | 4/20 | 0.36 |
| ▸ | BACE1 | P56817 | 2/20 | 0.35 |
| ▸ | IDO1 | P14902 | 2/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6494578 | 0.78 | CYP11B1 (0.34) | IDO1CYP11B1CYP11B2HTR2CSLC6A4 | |
| SCHEMBL23100772 | 0.76 | CHRM4 (0.38) | MAOAMAOBIDO1CYP11B1CYP11B2 | |
| SCHEMBL6491413 | 0.75 | ACHE (0.48) | MAOAMAOBACHESLC6A4 | |
| SCHEMBL18347078 | 0.75 | SLC6A4 (0.47) | IDO1CYP11B1HTR2CSLC6A4HTR2B | |
| SCHEMBL837704 | 0.75 | SLC6A4 (0.47) | IDO1CYP11B1HTR2CSLC6A4HTR2B | |
| SCHEMBL18347073 | 0.75 | SLC6A4 (0.47) | IDO1CYP11B1HTR2CSLC6A4HTR2B | |
| SCHEMBL4533624 | 0.74 | CYP1A2 (0.49) | MAOAMAOBBACE1CYP11B1CYP11B2 | |
| SCHEMBL6482195 | 0.74 | HTR2A (0.47) | BACE1IDO1ADRA2BADRA2CHTR2C | |
| SCHEMBL17729306 | 0.74 | IDO1 (0.42) | IDO1CYP11B1ACHEHTR6HTR2C | |
| SCHEMBL14349183 | 0.71 | HTR2C (0.38) | IDO1HTR2CSLC6A4HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6919335-B2 | Administering a therapeutically effective amount of a heterocyclic compound to the patient for the treatment of inosine monophosphate dehydrogenase associated disorders, such as allograft rejection | BRISTOL-MYERS SQUIBB CO. (US) | 2005-07-19 | — | — | US | disclosed |
| US-20020040022-A1 | Heterocycles that are inhibitors of IMPDH enzyme | BRISTOL-MYERS SQUIBB COMPANY | 2002-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040022-A1 | Heterocycles that are inhibitors of IMPDH enzyme | XDH, IMPDH1, IMPDH2 | MAOA 367/4885MAOB 336/4885BACE1 1718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.